Trends in Adherence to a Revised Risk Management Program Designed to Decrease or Eliminate Isotretinoin-Exposed Pregnancies
Open Access
- 1 May 2005
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 141 (5), 563-569
- https://doi.org/10.1001/archderm.141.5.563
Abstract
Isotretinoin (Accutane; Hoffmann-La Roche Inc, Nutley, NJ), first approved in the United States in 1982, is indicated to treat severe, recalcitrant, nodular, cystic acne. This form of acne is painful, permanently disfiguring, and does not respond to other acne treatments. Isotretinoin is uniquely effective for this condition, but its use carries significant potential risks, including birth defects and intrauterine fetal death.Keywords
This publication has 5 references indexed in Scilit:
- Using Telephone Interviews to Reduce Nonresponse Bias to Mail Surveys of Health Plan MembersMedical Care, 2002
- A national survey of U.S. pharmacists in 2000: Assessing nonresponse bias of a survey methodologyAAPS PharmSci, 2001
- Isotretinoin Use and Risk of Depression, Psychotic Symptoms, Suicide, and Attempted SuicideArchives of Dermatology, 2000
- A Pregnancy-Prevention Program in Women of Childbearing Age Receiving IsotretinoinNew England Journal of Medicine, 1995
- A COMPARISON OF RESPONSES TO MAILED QUESTIONNAIRES AND TELEPHONE INTERVIEWS IN A MIXED MODE HEALTH SURVEY1American Journal of Epidemiology, 1987